View Press Releases
MIB Agents Awards $100,000 Grant for Pediatric Osteosarcoma Research at MD Anderson
FOR IMMEDIATE RELEASE
MIB Agents Awards $100,000 Grant for
Pediatric Osteosarcoma Research at MD Anderson
Grant part of nonprofit’s Osteosarcoma Program to Move
Rare Bone Cancer Research Forward
HOUSTON, TX – December 2, 2022-- MIB Agents, a leading pediatric osteosarcoma nonprofit dedicated to Making It Better for its community of patients, caregivers, doctors, and researchers, has awarded a $100,000 research grant to Andy Livingston, M.D., a clinician and researcher in Sarcoma Medical Oncology and in Pediatric Oncology at The University of Texas MD Anderson Cancer Center. Ann Graham, Founder and Executive Director of MIB Agents, and Christina Ip-Toma, MIB Agents’ Director of Scientific Programs, presented the award to Dr. Livingston on Dec. 1 in Houston.
The grant is part of MIB Agents’ annual OutSmarting Osteosarcoma research grantsprogram. Established in 2017, this grant is awarded to a project focused on moving research forward for osteosarcoma patients. Osteosarcoma is an aggressive, malignant primary bone cancer affecting between 800-900 people in the U.S. each year and is the most common bone cancer affecting children and young adults.
“I am grateful to MIB Agents for this grant to support my research and our work to develop new treatment strategies for patients with osteosarcoma and other bone sarcomas,” said Livingston.
Livingston’s work focuses on teens and young adults with cancer. He is co-director of MD Anderson’s Adolescent and Young Adult (AYA), offering a range of support services, a scholarship fund and opportunities to meet people who understand how lonely and isolating cancer can be for young adults.
“This grant has been awarded to Dr. Livingston to support his great work in researching new treatments for osteosarcoma,” said Ann Graham, Founder and Executive Director of MIB Agents. “Sadly, it has been 45 years since a new treatment has come to market, but, through programs like Osteosarcoma, we aim to give patients and their families hope for better treatment options.”
MIB Agents Osteosarcoma grants are supported by MIB Agents Family Funds, a group comprised of osteosarcoma patients and families who raise funds in honor of an , a patient currently battling osteosarcomaor an , a loved one who has passed.
Collaboration among the scientific and patient community is a key hallmark of MIB Agents that makes the Osteosarcoma grant process unique. Not only does the patient community partner to fund this grant every year, but they have an active voice in the grant review process.
To submit an application, and for more information about eligibility and requirements for Osteosarcoma, click here. Applications must be submittedon the Proposal Central online platform by February 3, 2023. Award notification will be in early May 2023.
About MIB Agents
Founded in 2012, MIB Agents is a leading pediatric osteosarcoma nonprofit dedicated to making it better for our community of patients, caregivers, doctors, and researchers through programs, education, and research.